Dicerna Pharmaceuticals, Inc. (DRNA) Income Statement Analysis

See more : Trine II Acquisition Corp. (TRAQ) Income Statement Analysis – Financial Results

Complete financial analysis of Dicerna Pharmaceuticals, Inc. (DRNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dicerna Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Landsea Green Life Service Company Limited (1965.HK) Income Statement Analysis – Financial Results
COPRO-HOLDINGS. Co., Ltd. (7059.T) Income Statement Analysis – Financial Results
China Fangda Group Co., Ltd. (200055.SZ) Income Statement Analysis – Financial Results
JATT Acquisition Corp (JATT) Income Statement Analysis – Financial Results
Horizon Oil Limited (HZN.AX) Income Statement Analysis – Financial Results

Dicerna Pharmaceuticals, Inc. (DRNA)

Industry: Biotechnology

Sector: Healthcare

Website: https://dicerna.com

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Metric	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	164.31M	23.90M	6.18M	2.28M	295.00K	184.00K	0.00	0.00	7.02M	7.91M
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	164.31M	23.90M	6.18M	2.28M	295.00K	184.00K	0.00	0.00	7.02M	7.91M
Gross Profit Ratio	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	100.00%	100.00%
Research & Development	205.38M	109.34M	45.71M	36.98M	41.69M	43.97M	29.45M	11.56M	11.57M	10.71M
General & Administrative	72.13M	42.75M	21.69M	25.88M	18.35M	19.24M	15.65M	5.82M	4.70M	4.82M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	72.13M	42.75M	21.69M	25.88M	18.35M	19.24M	15.65M	5.82M	4.70M	4.82M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	277.52M	152.09M	67.40M	62.86M	60.04M	63.21M	45.10M	17.38M	16.27M	15.52M
Cost & Expenses	277.52M	152.09M	67.40M	62.86M	60.04M	63.21M	45.10M	17.38M	16.27M	15.52M
Interest Income	6.01M	7.54M	2.10M	539.00K	235.00K	188.00K	63.00K	4.00K	2.00K	3.00K
Interest Expense	20.00K	3.00K	603.00K	0.00	0.00	0.00	199.00K	952.00K	1.34M	997.00K
Depreciation & Amortization	2.22M	1.25M	774.00K	778.00K	840.00K	727.00K	848.00K	523.00K	551.00K	474.00K
EBITDA	-110.51M	-119.20M	-87.48M	-59.27M	-58.67M	-62.11M	-46.89M	-17.04M	-8.23M	-7.09M
EBITDA Ratio	-67.26%	-498.67%	-1,416.39%	-2,602.99%	-19,889.15%	-33,756.52%	0.00%	0.00%	-117.29%	-89.59%
Operating Income	-113.21M	-128.19M	-61.22M	-60.59M	-59.75M	-63.03M	-45.10M	-17.38M	-9.25M	-7.61M
Operating Income Ratio	-68.90%	-536.25%	-991.26%	-2,660.83%	-20,253.56%	-34,253.80%	0.00%	0.00%	-131.86%	-96.27%
Total Other Income/Expenses	461.00K	7.73M	-27.63M	539.00K	235.00K	188.00K	-2.84M	-1.14M	-871.00K	-943.00K
Income Before Tax	-112.75M	-120.46M	-88.85M	-60.05M	-59.51M	-62.84M	-47.94M	-18.52M	-10.12M	-8.56M
Income Before Tax Ratio	-68.62%	-503.93%	-1,438.68%	-2,637.15%	-20,173.90%	-34,151.63%	0.00%	0.00%	-144.28%	-108.19%
Income Tax Expense	481.00K	7.73M	-27.03M	539.00K	235.00K	188.00K	-2.64M	-188.00K	471.00K	54.00K
Net Income	-112.75M	-120.46M	-88.85M	-60.05M	-59.51M	-62.84M	-47.94M	-18.52M	-10.12M	-8.56M
Net Income Ratio	-68.62%	-503.93%	-1,438.68%	-2,637.15%	-20,173.90%	-34,151.63%	0.00%	0.00%	-144.28%	-108.19%
EPS	-1.51	-1.76	-1.60	-2.90	-2.87	-3.09	-2.98	-1.11	-4.95	-0.11
EPS Diluted	-1.51	-1.76	-1.60	-2.90	-2.87	-3.09	-2.98	-1.11	-4.95	-0.11
Weighted Avg Shares Out	74.52M	68.43M	55.62M	20.72M	20.72M	20.32M	16.07M	16.63M	2.05M	77.91M
Weighted Avg Shares Out (Dil)	74.52M	68.43M	55.62M	20.72M	20.72M	20.32M	16.07M	16.63M	2.05M	77.91M

Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today

November 18, 2021fool.com

A juicy buyout offer from Novo Nordisk is giving Dicerna shareholders a big reason to cheer.

LCID, RIVN, FSR: Why Are EV Stocks Down Today?

November 18, 2021investorplace.com

We're taking a look at why EV stocks are down today and there are a couple of reasons shares of investors' favorites are falling. The post LCID, RIVN, FSR: Why Are EV Stocks Down Today?

Shareholder Alert: Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtained a Fair Price in its going private transaction with Novo Nordisk

November 18, 2021prnewswire.com

MILWAUKEE, Nov. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating Dicerna (Nasdaq: DRNA), for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. Click here to learn how to join the action: https://www.ademilaw.com/case/dicerna-pharmaceuticals-inc...

Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DRNA

November 18, 2021businesswire.com

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders. Halper Sadeh encourages Dicerna...

Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DRNA

November 18, 2021businesswire.com

DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today

November 18, 2021investorplace.com

Dicerna Pharmaceuticals (DRNA) stock is surging higher on Thursday following news of a massive $3.3 billion deal with Novo Nordisk. The post DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today appeared first on InvestorPlace.

Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know

November 18, 2021benzinga.com

Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021. "The acquisition of...